161 Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177 Lu in Preclinical Models of Ovarian Cancer
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.269078 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Tihomir Zh Todorov und 9 weiteren Autor:innen. Beteiligte Einrichtung: PSI Center for Life Sciences, Villigen, Switzerland. Hauptthemen laut MEDLINE: Neural Cell Adhesion Molecule L1, Ovarian Neoplasms, Radioimmunotherapy, Neoplastic Stem Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Cancer stem cells (CSCs) are highly tumorigenic, self-renewable cells with a key role in tumor relapse, metastasis, and therapy resistance. Effective CSC-targeted therapies remain an unmet clinical need, strongly dependent on the selection of suitable targets and thorough validation of therapeutic agents. L1 cell adhesion molecule (L1CAM) is a targetable CSC-associated biomarker aberrantly expressed in various malignancies, including ovarian cancer (OC). 161Tb is attractive for clinical application because of its substantial emission of conversion electrons/Auger electrons as well as β- emission. Leveraging the high cytotoxicity of conversion electrons/Auger electrons, 161Tb is promising for radioimmunotherapy against radioresistant tumor cells such as CSCs. The aim of this study was to confirm the presence of L1CAM+/CD133+ ovarian CSCs in patient samples and preclinically investigate, in a tumor prevention mouse model, 161Tb-based anti-L1CAM radioimmunotherapy as a new therapeutic modality against CSCs compared with 177Lu-based anti-L1CAM radioimmunotherapy.
Methods
L1CAM+/CD133+ CSCs were examined in OC samples by immunofluorescence. After radiolabeling anti-L1CAM DOTA-chCE7 with 177Lu or 161Tb and purification, we assessed radioimmunoconjugate quality by determining the radiochemical purity and the immunoreactive fraction. The internalized and membrane-bound fractions and the radiocytotoxicity of radiolabeled DOTA-chCE7 were evaluated with cell uptake and cell proliferation assays. Ovarian L1CAM+/CD133+ CSCs were sorted via fluorescence-activated cell sorting from OVCAR8 and SKOV3ip cells and inoculated into immunocompromised mice, who then received treatment with [177Lu]Lu-DOTA-chCE7 or [161Tb]Tb-DOTA-chCE7.
Results
L1CAM+/CD133+ CSCs (0.3%-21%) were confirmed in samples from patients who were chemotherapy-naïve or had relapsed OC. [177Lu]Lu-DOTA-chCE7 and [161Tb]Tb-DOTA-chCE7 were produced with high radiochemical purity and retained 76%-96% immunoreactivity. Cell uptake after 15 h ranged from 50% to 75% for both radioimmunoconjugates. [161Tb]Tb-DOTA-chCE7 showed significantly increased cytotoxicity, eliminating all ovarian CSCs and tumor cells differentiated from the CSCs in vivo, compared with [177Lu]Lu-DOTA-chCE7 (3 tumors in OVCAR8 group and 1 tumor in SKOV3ip group). Follow-up tumor analysis confirmed that sorted ovarian L1CAM+/CD133+ CSCs regenerated the tumor heterogeneity in vivo.
Conclusion
This work addresses the critical need for CSC-specific therapies in the clinics by establishing 161Tb-based anti-L1CAM radioimmunotherapy as a novel therapeutic modality against CSCs. We found that 161Tb-based anti-L1CAM radioimmunotherapy eliminated ovarian CSCs more efficiently than 177Lu-based anti-L1CAM radioimmunotherapy, emphasizing its promising therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PSI Center for Life Sciences, Villigen, Switzerland.
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
- Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, Switzerland; and.
- Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, Switzerland.
- PSI Center for Life Sciences, Villigen, Switzerland; juergen.gruenberg@psi.ch roger.schibli@psi.ch.
Zitieren
APA
Todorov, T. Z., Coelho, R., Dellea, S., Jacob, F., Heinzelmann-Schwarz, V., Grundler, P. V., van der Meulen, N. P., Béhé, M. P., Schibli, R., & Grünberg, J. (2025). 161 Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177 Lu in Preclinical Models of Ovarian Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.269078
Vancouver
Todorov TZ, Coelho R, Dellea S, Jacob F, Heinzelmann-Schwarz V, Grundler PV, et al. 161 Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177 Lu in Preclinical Models of Ovarian Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.269078
BibTeX
@article{Todorov2025,
author = {Todorov, Tihomir Zh and Coelho, Ricardo and Dellea, Sharon and Jacob, Francis and Heinzelmann-Schwarz, Viola and Grundler, Pascal V and van der Meulen, Nicholas P and Béhé, Martin P and Schibli, Roger and Grünberg, Jürgen},
title = {161 Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177 Lu in Preclinical Models of Ovarian Cancer},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.269078}
}
EUVIMED